CVE-2014-2387

Description

Pen 0.18.0 has Insecure Temporary File Creation vulnerabilities

Category

4.4
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.10%
Third-Party Advisory openwall.com Third-Party Advisory securityfocus.com Third-Party Advisory redhat.com Third-Party Advisory suse.com Third-Party Advisory ibmcloud.com Third-Party Advisory debian.org
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://security-tracker.debian.org/tracker/CVE-2014-2387 third party advisory
https://bugzilla.redhat.com/show_bug.cgi?id=CVE-2014-2387 issue tracking third party advisory
https://bugzilla.suse.com/show_bug.cgi?id=CVE-2014-2387 issue tracking third party advisory
https://exchange.xforce.ibmcloud.com/vulnerabilities/91992 vdb entry third party advisory
http://www.openwall.com/lists/oss-security/2014/03/13/5 third party advisory mailing list
http://www.openwall.com/lists/oss-security/2014/03/14/2 mailing list
http://www.securityfocus.com/bid/66214 vdb entry third party advisory

Frequently Asked Questions

What is the severity of CVE-2014-2387?
CVE-2014-2387 has been scored as a medium severity vulnerability.
How to fix CVE-2014-2387?
To fix CVE-2014-2387, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2014-2387 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2014-2387 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.